Spero Therapeutics (SPRO) Short-term Investments (2018 - 2022)

Spero Therapeutics (SPRO) has 5 years of Short-term Investments data on file, last reported at $49.9 million in Q1 2022.

• For the quarter ending Q1 2022, Short-term Investments rose 29.04% year-over-year to $49.9 million; the trailing twelve-month figure through Mar 2022 stood at $49.9 million (up 29.04% YoY), and the FY2021 full-year result was $33.8 million, down 18.9% from the prior year.
• Short-term Investments for Q1 2022 stood at $49.9 million, up from $33.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $90.7 million in Q3 2018 and bottomed at $2.0 million in Q3 2020.
• The 5-year median for Short-term Investments is $33.8 million (2021), against an average of $37.5 million.
• The widest annual swing landed in 2020, when Short-term Investments tumbled 95.85%; it then surged 427.37% in 2021.
• A 5-year view of Short-term Investments shows it stood at $81.4 million in 2018, then sank by 35.7% to $52.3 million in 2019, then decreased by 20.3% to $41.7 million in 2020, then declined by 18.9% to $33.8 million in 2021, then surged by 47.42% to $49.9 million in 2022.
• The last three Short-term Investments figures came in at $49.9 million (Q1 2022), $33.8 million (Q4 2021), and $10.6 million (Q3 2021), per Business Quant data.

Peer Comparison